SABCS 2024: New Research Assesses iCAD's Image Based AI-Risk, Detection, and Breast Arterial Calcifications (BAC) Assessment Across Diverse Populations

Core Insights - iCAD, Inc. announced that four novel AI-driven breast cancer research abstracts have been accepted for presentation at the 2024 San Antonio Breast Cancer Symposium, focusing on improving detection and risk prediction accuracy [1][2][3] Group 1: Research Highlights - The studies presented at the symposium emphasize the role of iCAD's ProFound AI Breast Health Suite in enhancing early breast cancer detection and addressing health disparities across diverse populations [4][5] - A study demonstrated that an image-derived AI-risk model outperformed the clinical Tyrer-Cuzick v8 risk model, indicating its potential for primary prevention of breast cancer [3][9] - Research on the prevalence of Breast Arterial Calcifications (BAC) showed that AI algorithms could effectively identify BAC across different racial groups, suggesting its utility as a cardiovascular biomarker [5][6] Group 2: Clinical Implications - AI-driven short-term breast cancer risk assessment scores were validated to be effective across racial subgroups, indicating consistent accuracy in risk stratification [6][7] - The findings suggest that AI can improve diagnostic accuracy and patient outcomes by providing equitable breast cancer risk assessments, particularly for women with dense breast tissue [7][8] - The potential for AI to enhance early cardiovascular intervention in patients with breast cancer was highlighted, indicating a broader application of AI in healthcare [5][9] Group 3: Company Overview - iCAD, Inc. is a global leader in AI-powered cancer detection solutions, with its ProFound Breast Health Suite being utilized by thousands of providers in over 50 countries [11] - The company has read more than 40 million mammograms worldwide in the last five years, showcasing its significant market presence and impact on breast cancer detection [11]